Neha Vapiwala, MD
The Abramson Cancer Center of the University of Pennsylvania
Last Modified: September 27, 2005
Jun 3, 2014 - For patients with non-small-cell lung cancer who have relapsed after initial treatment, the addition of the anti-angiogenesis drug ramucirumab to standard docetaxel chemotherapy extends survival. This finding was presented at the annual meeting of the American Society of Clinical Oncology, held from May 30 to June 3 in Chicago.
Aug 18, 2014
May 20, 2013